A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 4,54 (-19,93%). A mediana é € 4,54 (-19,93%).
| Comprar |
0 |
| Manter |
2 |
| Vender |
2 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
Embecta exceeds Q3 expectations and raises full-year outlook
Embecta reported adjusted EPS of $0.56 and revenue of $271.7 million for Q3 2026, significantly beating consensus estimates. The company raised its forecasts for adjusted operating margin to 23.5–24% and adjusted EPS to $1.80–1.90, but left its 2026 revenue guidance unchanged. Despite a year‑over‑year revenue decline, Embecta benefited from cost cuts, the contribution from the acquisition of Owen Mumford and a sequential improvement in results; however, the U.S. business remains under pressure. » Mais em de.investing.com
Embecta resets U.S. outlook after retailer share loss and pushes GLP-1, Owen Mumford diversification
Embecta cut its U.S. guidance after a challenging quarter marked by loss of shelf position at a major retailer—attributed mainly to price pressure—softer insulin pen prescriptions and inventory adjustments. CEO Devdatt Kurdikar said the company is assessing whether the weakness is temporary or structural amid rising GLP-1 affordability and insurance changes. Embecta is accelerating diversification via lower‑priced pen needles and syringes, a GLP‑1 B2B channel and the pending Owen Mumford acquisition while targeting about $100 million in free cash flow and prioritizing debt reduction and buybacks. » Mais em finance.yahoo.com
S&P downgrades Embecta to B after sales decline in pen needles
S&P Global Ratings cut Embecta’s rating from B+ to B with a stable outlook after second fiscal quarter sales fell 14%. Reasons cited include roughly 20% currency‑adjusted revenue weakness in insulin pen needles, market share losses to a lower‑priced competitor, and weaker US market demand (lower insulin usage, a shift to cheaper channels, increased use of automated systems and GLP‑1 drugs). S&P expects about a 6% sales decline in 2026, an adjusted margin down roughly 800 basis points to 29%, and leverage of 4.5–5x; the acquisition of Owen Mumford is expected to be financed via the revolving credit facility and the dividend will be cut to reduce debt. » Mais em de.investing.com
Embecta misses Q2 2026 forecasts significantly, stock falls 44% premarket
Embecta reported Q2 2026 EPS of $0.27 versus $0.42 expected and revenue of $221.8 million versus $235.66 million expected. Revenue fell 14.4% year-on-year, driven by a 29.4% decline in the US business, prompting the company to lower its full-year guidance. The stock plunged in premarket trading from $9.25 to $5.15. Management announced a review of the cost and organizational structure, brand and product initiatives, and the integration of Owen Mumford as a strategic move. » Mais em de.investing.com
Embecta to acquire Owen Mumford for up to £150 million
Embecta has signed a definitive agreement to acquire British medical‑technology manufacturer Owen Mumford. On closing Embecta will pay £100 million in cash plus up to £50 million in contingent payments, depending on net sales of the Aidaptus autoinjector platform in the three years after closing. Owen Mumford recorded net sales of £69.4 million in 2025; the transaction is expected to close in the third quarter of fiscal 2026, subject to regulatory approvals. Embecta expects growth and long‑term accretion from 2027 but foresees a dilution of adjusted net income in 2027; financing will be partly provided through its revolving credit facility. » Mais em de.investing.com
Dividendos históricos Dividendos
Todos os indicadores de dividendos Todos os indicadoresDados financeiros da empresa
| (EUR) | junho de 2026 | YoY |
|---|---|---|
| Receitas | 238,07 mi | 5,04% |
| Ganho bruto | 134,32 mi | 18,81% |
| Ganho líquido | 18,49 mi | 52,11% |
| EBITDA | 56,69 mi | 39,58% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 332,62 mi |
Número de ações | 56,66 mi |
Máximo/mínimo de 52 semanas | € 13,46 - € 2,52 |
Rentabilidade de dividendos | 4,87% |
Dividendos TTM | € 0,28 |
Beta | 0,81 |
PER (PE Ratio) | 4,34 |
PEG (PEG Ratio) | 0,88 |
P/VC (PB Ratio) | -0,62 |
P/V (PS Ratio) | 0,36 |
Perfil da empresa
A Embecta Corp., uma empresa de dispositivos médicos, dedica-se à oferta de diversas soluções para melhorar a saúde e o bem-estar das pessoas que vivem com diabetes. Os seus produtos incluem agulhas para canetas, seringas e dispositivos de segurança, bem como aplicações digitais que auxiliam as pessoas na gestão da sua diabetes. A empresa vende os seus produtos principalmente a grossistas e distribuidores nos Estados Unidos e a nível internacional. A Embecta Corp. foi fundada em 1924 e tem sede em Parsippany, Nova Jérsia. A Embecta Corp. (NasdaqGS:EMBC) opera de forma independente da Becton, Dickinson and Company desde 1 de abril de 2022.
| Nome | Embecta Aktie |
| CEO | Devdatt Kurdikar |
| Sede | Parsippany,
nj EUA |
| Site | |
| Setor | Bens de consumo não essenciais |
| Indústria | Bens de consumo duradouros |
| Entrada em bolsa | 22/03/2022 |
| Colaboradores | 1.850 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | EMBC |
Frankfurt | JX7.F |
Düsseldorf | JX7.DU |
München | JX7.MU |